Vincent O'Neill - Jul 22, 2024 Form 4 Insider Report for BioXcel Therapeutics, Inc. (BTAI)

Role: Former Executive Vice President, Chief of Product Development and Medical Officer
Signature: /s/ Richard Steinhart, as Attorney-in-Fact for Vincent O'Neill
Stock symbol: BTAI
Transactions as of: Jul 22, 2024
Transactions value $: $0
Form type: 4
Date filed: 4/1/2025, 06:08 PM
Previous filing: Jun 18, 2024
Next filing: Sep 17, 2024
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BTAI	Stock Option (right to buy)	Award	$0	+1.88K		$0.00	1.88K	Jul 22, 2024	Common Stock	1.88K	$1.20	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Vincent O'Neill is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Id	Content
F1	The share amount has been adjusted to reflect the reverse stock split effective on February 7, 2025 whereby every sixteen shares issued and outstanding prior to the split were combined and converted into one share of common stock.
F2	The Reporting Person was granted an option to purchase 1,875 shares of common stock, which vests as to 50% on each of the first and second anniversaries of the grant date, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Due to the Reporting Person's termination of employment, the unvested Stock Option was forfeited.

Former Executive Vice President, Chief of Product Development and Medical Officer